GeoVax Labs (GOVX) to Release Quarterly Earnings on Tuesday

GeoVax Labs (NASDAQ:GOVX) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

GeoVax Labs Trading Up 1.6 %

Shares of NASDAQ GOVX opened at $1.95 on Friday. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18. The business’s 50 day moving average price is $2.50 and its 200 day moving average price is $2.56.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GOVX. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Monday, August 12th. Noble Financial raised their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th. Roth Mkm began coverage on GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price target for the company. Finally, Roth Capital upgraded GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 16th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.67.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.